Cargando…

Clinical implications of BRAF mutation test in colorectal cancer

Knowledge about the clinical significance of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) mutations in colorectal cancer (CRC) is growing. BRAF encodes a protein kinase involved with intracellular signaling and cell division. The gene product is a downstream effector of Kirsten Ras 1(KRAS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mojarad, Ehsan Nazemalhosseini, Farahani, Roya Kishani, Haghighi, Mahdi Montazer, Aghdaei, Hamid Asadzadeh, Kuppen, Peter JK, Zali, Mohammad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Institute for Gastroenterology and Liver Diseases 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017487/
https://www.ncbi.nlm.nih.gov/pubmed/24834238
_version_ 1782479962778894336
author Mojarad, Ehsan Nazemalhosseini
Farahani, Roya Kishani
Haghighi, Mahdi Montazer
Aghdaei, Hamid Asadzadeh
Kuppen, Peter JK
Zali, Mohammad Reza
author_facet Mojarad, Ehsan Nazemalhosseini
Farahani, Roya Kishani
Haghighi, Mahdi Montazer
Aghdaei, Hamid Asadzadeh
Kuppen, Peter JK
Zali, Mohammad Reza
author_sort Mojarad, Ehsan Nazemalhosseini
collection PubMed
description Knowledge about the clinical significance of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) mutations in colorectal cancer (CRC) is growing. BRAF encodes a protein kinase involved with intracellular signaling and cell division. The gene product is a downstream effector of Kirsten Ras 1(KRAS) within the RAS/RAF/MAPK cellular signaling pathway. Evidence suggests that BRAF mutations, like KRAS mutations, result in uncontrolled, non–growth factor-dependent cellular proliferation. Similar to the rationale that KRAS mutation precludes effective treatment with anti-EGFR drugs. Recently, BRAF mutation testing has been introduced into routine clinical laboratories because its significance has become clearer in terms of effect on pathogenesis of CRC, utility in differentiating sporadic CRC from Lynch syndrome (LS), prognosis, and potential for predicting patient outcome in response to targeted drug therapy. In this review we describe the impact of BRAF mutations for these aspects.
format Online
Article
Text
id pubmed-4017487
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Research Institute for Gastroenterology and Liver Diseases
record_format MEDLINE/PubMed
spelling pubmed-40174872014-05-15 Clinical implications of BRAF mutation test in colorectal cancer Mojarad, Ehsan Nazemalhosseini Farahani, Roya Kishani Haghighi, Mahdi Montazer Aghdaei, Hamid Asadzadeh Kuppen, Peter JK Zali, Mohammad Reza Gastroenterol Hepatol Bed Bench Review Article Knowledge about the clinical significance of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) mutations in colorectal cancer (CRC) is growing. BRAF encodes a protein kinase involved with intracellular signaling and cell division. The gene product is a downstream effector of Kirsten Ras 1(KRAS) within the RAS/RAF/MAPK cellular signaling pathway. Evidence suggests that BRAF mutations, like KRAS mutations, result in uncontrolled, non–growth factor-dependent cellular proliferation. Similar to the rationale that KRAS mutation precludes effective treatment with anti-EGFR drugs. Recently, BRAF mutation testing has been introduced into routine clinical laboratories because its significance has become clearer in terms of effect on pathogenesis of CRC, utility in differentiating sporadic CRC from Lynch syndrome (LS), prognosis, and potential for predicting patient outcome in response to targeted drug therapy. In this review we describe the impact of BRAF mutations for these aspects. Research Institute for Gastroenterology and Liver Diseases 2013 /pmc/articles/PMC4017487/ /pubmed/24834238 Text en Copyright © 2013 Research Institute for Gastroenterology and Liver Diseases http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Review Article
Mojarad, Ehsan Nazemalhosseini
Farahani, Roya Kishani
Haghighi, Mahdi Montazer
Aghdaei, Hamid Asadzadeh
Kuppen, Peter JK
Zali, Mohammad Reza
Clinical implications of BRAF mutation test in colorectal cancer
title Clinical implications of BRAF mutation test in colorectal cancer
title_full Clinical implications of BRAF mutation test in colorectal cancer
title_fullStr Clinical implications of BRAF mutation test in colorectal cancer
title_full_unstemmed Clinical implications of BRAF mutation test in colorectal cancer
title_short Clinical implications of BRAF mutation test in colorectal cancer
title_sort clinical implications of braf mutation test in colorectal cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017487/
https://www.ncbi.nlm.nih.gov/pubmed/24834238
work_keys_str_mv AT mojaradehsannazemalhosseini clinicalimplicationsofbrafmutationtestincolorectalcancer
AT farahaniroyakishani clinicalimplicationsofbrafmutationtestincolorectalcancer
AT haghighimahdimontazer clinicalimplicationsofbrafmutationtestincolorectalcancer
AT aghdaeihamidasadzadeh clinicalimplicationsofbrafmutationtestincolorectalcancer
AT kuppenpeterjk clinicalimplicationsofbrafmutationtestincolorectalcancer
AT zalimohammadreza clinicalimplicationsofbrafmutationtestincolorectalcancer